Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
Condition:   Mantle Cell Lymphoma (MCL) Intervention:   Sponsors:   Peking University Third Hospital;   Peking Union Medical College Hospital;   The Second Affiliated Hospital of Dalian Medical University;   Peking University First Hospital;   Beijing Tongren Hospital;   Beijing Hospital;   Beijing Tsinghua Changgeng Hospital;   China-Japa n Friendship Hospital;   307 Hospital of PLA;   Chinese PLA General Hospital;   First Affiliated Hospital of Harbin Medical University;   Harbin Medical University;   Baotou Cancer Hospital;   Beijing Shijitan Hospital, Capital Medical Unive...
Source: ClinicalTrials.gov - June 6, 2022 Category: Research Source Type: clinical trials

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Condition:   Lymphoma, Large B-Cell, Diffuse Interventions:   Biological: Zilovertamab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Biological: Rituximab;   Biological: Rituximab Biosimilar;   Drug: Prednisone;   Drug: Prednisolone Sponsor:   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2022 Category: Research Source Type: clinical trials

Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
Condition:   Mantle Cell Lymphoma (MCL) Intervention:   Sponsors:   Peking University Third Hospital;   Peking Union Medical College Hospital;   The Second Affiliated Hospital of Dalian Medical University;   Peking University First Hospital;   Beijing Tongren Hospital;   Beijing Hospital;   Beijing Tsinghua Changgeng Hospital;   China-Japa n Friendship Hospital;   307 Hospital of PLA;   Chinese PLA General Hospital;   First Affiliated Hospital of Harbin Medical University;   Harbin Medical University;   Baotou Cancer Hospital;   Beijing Shijitan Hospital, Capital Medical Unive...
Source: ClinicalTrials.gov - June 6, 2022 Category: Research Source Type: clinical trials

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Condition:   Lymphoma, Large B-Cell, Diffuse Interventions:   Biological: Zilovertamab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Biological: Rituximab;   Biological: Rituximab Biosimilar;   Drug: Prednisone;   Drug: Prednisolone Sponsor:   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2022 Category: Research Source Type: clinical trials

Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
Condition:   Mantle Cell Lymphoma (MCL) Intervention:   Sponsors:   Peking University Third Hospital;   Peking Union Medical College Hospital;   The Second Affiliated Hospital of Dalian Medical University;   Peking University First Hospital;   Beijing Tongren Hospital;   Beijing Hospital;   Beijing Tsinghua Changgeng Hospital;   China-Japa n Friendship Hospital;   307 Hospital of PLA;   Chinese PLA General Hospital;   First Affiliated Hospital of Harbin Medical University;   Harbin Medical University;   Baotou Cancer Hospital;   Beijing Shijitan Hospital, Capital Medical Unive...
Source: ClinicalTrials.gov - June 6, 2022 Category: Research Source Type: clinical trials

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Condition:   Lymphoma, Large B-Cell, Diffuse Interventions:   Biological: Zilovertamab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Biological: Rituximab;   Biological: Rituximab Biosimilar;   Drug: Prednisone;   Drug: Prednisolone Sponsor:   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2022 Category: Research Source Type: clinical trials

R-MTX-zanbrutinib in Secondary CNS Lymphoma
Condition:   Secondary Central Nervous System Lymphoma Intervention:   Drug: Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab Sponsor:   Peking University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2022 Category: Research Source Type: clinical trials